Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Receivables (2020 - 2025)

Oncology Institute (TOI) has disclosed Receivables for 6 consecutive years, with $60.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables rose 10.05% year-over-year to $60.0 million, compared with a TTM value of $60.0 million through Sep 2025, up 10.05%, and an annual FY2024 reading of $48.7 million, up 14.92% over the prior year.
  • Receivables was $60.0 million for Q3 2025 at Oncology Institute, up from $55.7 million in the prior quarter.
  • Across five years, Receivables topped out at $60.0 million in Q3 2025 and bottomed at $21.2 million in Q4 2021.
  • Average Receivables over 5 years is $44.9 million, with a median of $47.8 million recorded in 2023.
  • The sharpest move saw Receivables soared 90.33% in 2022, then fell 16.59% in 2025.
  • Year by year, Receivables stood at $21.2 million in 2021, then skyrocketed by 90.33% to $40.4 million in 2022, then rose by 6.13% to $42.9 million in 2023, then grew by 13.45% to $48.7 million in 2024, then grew by 23.21% to $60.0 million in 2025.
  • Business Quant data shows Receivables for TOI at $60.0 million in Q3 2025, $55.7 million in Q2 2025, and $49.3 million in Q1 2025.